Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries.

MLA

Li, Xiao, et al. “Cost-Effectiveness of Adding Oseltamivir to Primary Care for Influenza-like-Illness: Economic Evaluation alongside the Randomised Controlled ALIC4E Trial in 15 European Countries.” European Journal of Health Economics, vol. 24, no. 6, Aug. 2023, pp. 909–22. EBSCOhost, https://doi.org/10.1007/s10198-022-01521-2.

APA

Li, X., Bilcke, J., van der Velden, A. W., Bruyndonckx, R., Coenen, S., Bongard, E., de Paor, M., Chlabicz, S., Godycki-Cwirko, M., Francis, N., Aabenhus, R., Bucher, H. C., Colliers, A., De Sutter, A., Garcia-Sangenis, A., Glinz, D., Harbin, N. J., Kosiek, K., Lindbæk, M., & Lionis, C. (2023). Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries. European Journal of Health Economics, 24(6), 909–922. https://doi.org/10.1007/s10198-022-01521-2

Chicago

Li, Xiao, Joke Bilcke, Alike W. van der Velden, Robin Bruyndonckx, Samuel Coenen, Emily Bongard, Muirrean de Paor, et al. 2023. “Cost-Effectiveness of Adding Oseltamivir to Primary Care for Influenza-like-Illness: Economic Evaluation alongside the Randomised Controlled ALIC4E Trial in 15 European Countries.” European Journal of Health Economics 24 (6): 909–22. doi:10.1007/s10198-022-01521-2.